ezetimibe has been researched along with Hyperlipidemias in 149 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 70 (46.98) | 29.6817 |
| 2010's | 59 (39.60) | 24.3611 |
| 2020's | 20 (13.42) | 2.80 |
| Authors | Studies |
|---|---|
| Avendano, EE; Morin, RA; Nirmala, N | 1 |
| Carvajal-Gonzalez, S; Dullea, R; Furtado, JD; Nicholls, SJ; Ruotolo, G; Sacks, FM | 1 |
| Bae, JH; Chang, Y; Jang, JY; Jeong, SW; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, WM; Moon, JE; Yoo, JJ | 1 |
| Catapano, AL; Pirillo, A | 1 |
| Adamson, SS; Biddinger, SB; Bullock, K; Chahar, S; Clish, CB; Crooke, RM; de Ferranti, SD; Gearing, ME; Graham, MJ; Hagey, LR; Kidambi, S; Krawczyk, J; Levenson, AE; Ling, AV; Miao, J; Semova, I; Shin, DJ; Vicent, D; Williams, KA | 1 |
| Burnett, H; Cichewicz, A; Di Domenico, M; Durand, A; Fahrbach, K; Jindal, R; Reichelt, A; Tarpey, J; Viljoen, A | 1 |
| Chen, S; Du, Y; Li, Q; Liu, Q; Tan, C; Wang, QK; Wu, C; Xu, C; Yang, H; Zhang, H; Zhang, X; Zhu, Q | 1 |
| Aronow, WS; Bandyopadhyay, D; Devanabanda, AR; Ghosh, RK; Gupta, M; Mamas, M; Ray, KK; Tummala, R | 1 |
| Calabrò, P; De Ferrari, GM; Filardi, PP; Indolfi, C; Romeo, F | 1 |
| Boytsov, SA; Erlikh, AD; Kukava, NG; Pevsner, DV; Rytova, YK; Shakhnovich, RM; Tereschenko, SN | 1 |
| Almoshari, Y; Alshamrani, M; Butt, MH; Chaudhry, MA; Farooq, M; Iqbal, MH; Khan, MR; Mubeen, I; Qureshi, OS; Salawi, A; Zaman, M | 1 |
| Chang, J; Han, N; Hu, X; Li, H; Li, J; Liang, B; Liu, W; Lu, C; Meng, J; Shi, L; Wang, C; Wang, X; Xing, D; Yang, S; Zeng, J; Zhang, R | 1 |
| Hu, YX; Jing, Q; Li, FF; Liang, C; Liang, YL; Qin, YW; You, HM; Zhao, XX; Zhu, RF | 1 |
| Chen, P; Jia, A; Jiang, H; Liu, W; Sun, J; Xu, Q; Zhang, R | 1 |
| Landmesser, U; Sinning, D | 1 |
| Cao, Z; Chen, X; Liu, G; Liu, J; Wang, B; Wang, J; Wang, Y; Wu, Y; Xian, X; Xu, MJ; Yang, C; Zhang, F | 1 |
| Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS | 1 |
| Berklein, F; Feng, X; Habib, M; Lin, PJ; Rane, PB | 1 |
| Piszczatoski, C; Powell, J | 1 |
| Agnihotri, VV; Agrawal, YO; Goyal, SN; Mahajan, HS; Mahajan, UB; Nilange, MS; Ojha, S; Patil, CR; Sharma, C | 1 |
| Chmiel, K; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Paluch, M | 1 |
| Borén, J; Bruckert, E; Catapano, AL; Chapman, MJ; Fazio, S; Ference, BA; Ginsberg, HN; Graham, I; Hegele, RA; Horton, JD; Krauss, RM; Landmesser, U; Laufs, U; Masana, L; Nicholls, SJ; Nordestgaard, BG; Packard, CJ; Raal, FJ; Ray, KK; Schunkert, H; Stock, JK; Taskinen, MR; Tokgözoglu, L; van de Sluis, B; Watts, GF; Wiklund, O | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Grant, PJ | 1 |
| Cao, JT; Chen, K; Fan, YQ; Gao, L; Wang, CQ; Wang, Y; Xie, YS; Xu, ZJ; Yin, ZF; Zhang, HL | 1 |
| Beckett, RD; Koppen, LM; Rosene, A; Whitaker, A | 1 |
| Adam, S; Durrington, PN; Soran, H | 1 |
| Liu, CL; Xue, EZ; Zhang, MH | 1 |
| Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T | 1 |
| Han, SN; Tao, HL; Yang, WH; Yin, JJ; Zhang, LR | 1 |
| Banach, M; Corsini, A; Ruscica, M; Sahebkar, A; Sirtori, CR | 1 |
| Komine, T; Mu, S; Suzuki, H; Takada, T; Tanaka, Y; Yamamoto, H; Yamanashi, Y | 1 |
| Boban, D; Davidson, MH; Decaris, J; Glass, A; Hellerstein, M; Killion, S; Lu, Y; Luchoomun, J; Mohammad, H; Musliner, T; Neese, R; Neff, D; Tomassini, JE; Turner, S; Villegas, D; Voogt, J | 1 |
| Arya, N; Coutinho, EC; Dwivedi, J; Jain, KS; Khedkar, VM | 1 |
| Damasceno, NR; Fonseca, FA; Gidlund, M; Helfenstein, T; Izar, MC; Monteiro, AM; Moreira, FT; Neto, AM; Ramos, SC | 1 |
| Coffman, CJ; Crowley, MJ; Edelman, D; Fredrickson, SK; Jeffreys, AS; Melnyk, SD; Ostroff, JL | 1 |
| Albizem, M; Giugliano, RP; Kim, JB; Koren, MJ; Liu, T; Raal, FJ; Roth, EM; Sabatine, MS; Scott, R; Somaratne, R; Stein, EA; Sullivan, D; Wasserman, SM; Weiss, R; Yang, J | 1 |
| Ballantyne, CM; Blom, DJ; Bolognese, M; Burgess, L; Ceska, R; Hala, T; Kim, JB; Koren, MJ; Lillestol, MJ; Monsalvo, ML; Roth, E; Scott, R; Stein, EA; Toth, PD; Tsirtsonis, K; Wasserman, SM | 1 |
| Jain, M; Zafrir, B | 1 |
| Balogh, I; Berta, E; Bodor, M; Harangi, M; Paragh, G; Seres, I; Varga, V; Zsíros, N | 1 |
| Castaldo, RS | 1 |
| Kukharchuk, VV; Sumarokov, AB | 1 |
| Adibkia, K; Barzegar-Jalali, M; Garjani, A; Hamishehkar, H; Jahangiri, A; Javadzadeh, Y; Rameshrad, M | 1 |
| Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B | 1 |
| Adibkia, K; Asadpour-Zeynali, K; Barzegar-Jalali, M; Garjani, A; Hamishehkar, H; Jahangiri, A; Javadzadeh, Y | 1 |
| Keating, GM | 1 |
| Kobayashi, T; Kurozumi, A; Masuda, D; Mori, H; Okada, Y; Tanaka, Y; Yamashita, S | 1 |
| Correia, LC; Garcia, MM; Góes, PM; Guimarães, AC; Ladeia, AM; Lima, PR; Rodrigues, MG; Silva, Mde L; Silva, PF; Varela, CG | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Ogawa, H; Yamaguchi, J | 1 |
| Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S | 1 |
| Gartlehner, G; Glechner, A; Kaminski-Hartenthaler, A; Mahlknecht, P; Nußbaumer, B | 1 |
| Bilir, B; Ersoy, U; Gunaydin, S; Ozdemir, A; Sertbas, M; Sertbas, Y | 1 |
| Ferreira, AM; Marques da Silva, P | 1 |
| Csécsei, P; Karádi, Z; Lovadi, E; Lovig, C; Szapáry, L | 1 |
| Cziraky, MJ; Fox, KM; Gandra, SR; Paoli, CJ; Punekar, RS; Richhariya, A; Toth, PP | 1 |
| Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Farnier, M; Kush, D; Mitchel, YB; Perevozskaya, I; Taggart, WV | 1 |
| Robinson, JG | 1 |
| Derdemezis, CS; Elisaf, MS; Filippatos, TD; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD | 1 |
| Chen, JH; Liao, JK; Lin, LJ; Liu, PY; Liu, YW | 1 |
| Guthrie, R | 1 |
| Ansell, BJ | 2 |
| Anaya, F; Rodríguez-Ferrero, ML | 1 |
| Goldberg, AC; Hou, R | 1 |
| Couture, P; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Inagaki, M; Ishigami, M; Masuda, D; Nakagawa-Toyama, Y; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tsubakio-Yamamoto, K; Yamashita, S | 1 |
| Pasternak, RC; Tershakovec, AM; Veltri, EP | 1 |
| Visseren, FL; Westerink, J | 1 |
| Pernow, J; Rydén, L; Settergren, M | 1 |
| Kole, LA | 1 |
| Bangit, JR; Batsell, RR; John, S; Molinella, R; Reddy, KJ; Singh, M; Varghese, S; Zaheer, MS | 1 |
| Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE | 1 |
| Ben-Yehuda, O; Bird, S; Constance, C; Hanson, ME; Jones-Burton, C; Lee, R; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Balci, H; Caner, M; Ercan, MA; Genc, H; Karter, YH; Sipahioglu, F; Turfaner, N; Uzun, H | 1 |
| Phillips, W; Schaefer, S | 1 |
| Corsini, A; Poli, A | 1 |
| Benou, A; Fourtounas, C; Goumenos, D; Kalliakmani, P; Koukoulaki, M; Papachristou, E; Roumeliotou, M; Savvidaki, E; Vlachojannis, JG | 1 |
| Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S | 1 |
| Agouridis, AP; Elisaf, MS; Filippatos, TD; Tsimihodimos, V | 1 |
| Enko, K; Ito, H; Kohno, K; Kusano, KF; Miyoshi, T; Morita, H; Nakamura, K; Yunoki, K | 1 |
| Chong, E; Poh, KK; Shen, L | 1 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Abramson, BL; Benlian, P; Hanson, ME; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 1 |
| Attitalla, IH | 1 |
| Asano, R; Hagiwara, N; Seki, A; Sumiyoshi, T; Tobaru, T | 1 |
| Babageorgakas, P; Bouchliou, I; Kotsianidis, I; Margaritis, D; Miltiades, P; Nakou, E; Spanoudakis, E; Stakos, DA; Tziakas, DN | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Al-Sarraf, A; Frohlich, J; Li, M; Mattman, A | 1 |
| Inazumi, K; Kawakami, C; Kikuchi, K; Koike, H; Miyazaki, T; Nezu, U; Ono, K; Orime, K; Sato, K; Sato, M; Shirakawa, J; Terauchi, Y; Wakasugi, T; Watanabe, S; Yamakawa, T | 1 |
| Hiramitsu, S; Ishii, J; Kitagawa, F; Matsui, S; Miyagishima, K; Naruse, H; Ozaki, Y; Shiino, K | 1 |
| Critchley, WR; Shah, MK; Shaw, SM; Williams, SG; Yonan, N | 1 |
| Császár, A; Márk, L | 1 |
| Ballantyne, CM; Xydakis, AM | 1 |
| Brown, AS | 1 |
| Davidson, MH | 2 |
| Clearfield, MB | 1 |
| Owen, OG | 1 |
| Brown, WV | 1 |
| Cottrell, DA; Falko, JM; Marshall, BJ | 1 |
| Busch, RS; Kane, MP; Stroup, JS | 1 |
| Steiner, G | 1 |
| Ballantyne, CM | 1 |
| Krone, W; Müller-Wieland, D | 1 |
| King, H; Kreul, S; Reis, M; Ziajka, PE | 1 |
| Roberts, WC | 1 |
| Nash, DT | 1 |
| Vanhanen, H | 1 |
| Turley, SD | 1 |
| Davidson, MH; Toth, PP | 1 |
| Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P | 1 |
| Shepherd, J | 1 |
| Hegele, RA; Wang, J; Williams, CM | 1 |
| Schäfer, J | 1 |
| Davies, MJ; Farnier, M; Freeman, MW; Gumbiner, B; Macdonell, G; Mitchel, YB; Perevozskaya, I | 1 |
| Stalenhoef, AF | 1 |
| von Hodenberg, E | 1 |
| Chik, G; Doherty, E; Lumb, PJ; Wierzbicki, AS | 1 |
| Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ | 1 |
| Borja, J | 1 |
| Ducobu, J | 1 |
| Kastelein, JJ; Sankatsing, RR | 1 |
| Lee, S | 1 |
| Balbisi, EA | 1 |
| Buchanan, C; Corbett, J; Nelson, E; Shihab, F; Smith, L | 1 |
| Giral, P; Jublanc, C; Turpin, G | 1 |
| Francis, GA; Gilchrist, DM; Gyenes, GT; Opgenorth, A; Pearson, GJ; Romney, JS | 1 |
| Chun, P; Chung, S; Moon, YS | 1 |
| Balcerak, M; Broncel, M; Chojnowska-Jezierska, J | 1 |
| Farnier, M | 2 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Davis, HR; Veltri, EP | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Robins, DN | 1 |
| Bouknight, P; Heffington, M; Mackler, L | 1 |
| Berthold, HK; Giannakidou, E; Gouni-Berthold, I; Gylling, H; Hallikainen, M; Ko, Y; Krone, W; Mantzoros, CS; Patel, D; Plat, J; Seedorf, U; Soutar, AK; Stier, S | 1 |
| Kesäniemi, A | 1 |
| Davies, MJ; Farnier, M; Gumbiner, B; Macdonell, G; Musliner, TA; Perevozskaya, I; Tribble, DL | 1 |
| Yamashita, S | 1 |
| Austin, TM; Cook, JA; Davis, HR; Farley, C; Tetzloff, GG; van Heek, M | 1 |
50 review(s) available for ezetimibe and Hyperlipidemias
| Article | Year |
|---|---|
Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis.
Topics: Ezetimibe; HIV; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias | 2022 |
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis.
Topics: Anticholesteremic Agents; Bayes Theorem; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Network Meta-Analysis; Risk Factors; Treatment Outcome | 2022 |
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Topics: Atherosclerosis; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2022 |
[From statin revolution to gene silencing therapy: 50 years of evolution in the treatment of hypercholesterolemia].
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9 | 2022 |
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Patient Acuity; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors | 2021 |
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Topics: Atherosclerosis; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents | 2021 |
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Consensus; Epidemiologic Methods; Ezetimibe; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; PCSK9 Inhibitors | 2017 |
Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review.
Topics: Berberine; Biological Products; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipidemias; Lipids; Male | 2017 |
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States | 2018 |
Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.
Topics: Asian People; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin | 2019 |
Liptruzet: a combination of ezetimibe and atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Clinical Trials, Phase II as Topic; Ezetimibe; Female; Humans; Hyperlipidemias; Lipid Metabolism; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Randomized Controlled Trials as Topic; Serine Endopeptidases; Treatment Outcome | 2014 |
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
Topics: Animals; Azetidines; Bile Acids and Salts; Blood Glucose; Cholesterol Ester Transfer Proteins; Diabetes Mellitus; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Niacin | 2014 |
[Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia].
Topics: Anticholesteremic Agents; Azetidines; Drug Synergism; Ezetimibe; Humans; Hyperlipidemias; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
Evolocumab: A Review in Hyperlipidemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2016 |
Ezetimibe-Statin Combination Therapy.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Causality; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Risk Factors; Survival Rate; Treatment Outcome | 2016 |
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Simvastatin | 2017 |
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke | 2008 |
A review of trials evaluating nonstatin lipid-lowering therapies.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Niacin | 2009 |
Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Niacin | 2009 |
Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Risk Factors | 2010 |
Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.
Topics: Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism | 2011 |
Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sex Factors | 2011 |
Second line options for hyperlipidemia management after cardiac transplantation.
Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin | 2013 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Combination therapy for combined dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Triglycerides | 2002 |
Cholesterol absorption inhibitors: defining new options in lipid management.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Dietary Fats; Ezetimibe; Humans; Hyperlipidemias; Intestines; Treatment Outcome | 2003 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size | 2003 |
Newer pharmaceutical agents to treat lipid disorders.
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
The need for a different cholesterol lowering drug.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Artery Disease; Ezetimibe; Humans; Hyperlipidemias; Intestinal Absorption | 2003 |
Role of selective cholesterol absorption inhibition in the management of dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic | 2004 |
[Hyperlipidemia: therapeutic principles in clinical practice].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Insulin Resistance; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Risk Factors; Time Factors; Weight Loss | 2003 |
[Blocking the absorption of cholesterol in the treatment of hyperlipidemia--old and new ways of treatment].
Topics: Azetidines; Blood Chemical Analysis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2004 |
Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Absorption; Liver | 2004 |
Combination therapy in the management of complex dyslipidemias.
Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Niacin | 2004 |
Lipids in health and disease.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease; Ezetimibe; Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Liver | 2004 |
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines | 2005 |
[Optimization of cholesterol reduction principles and clinical results of dual inhibition].
Topics: Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Combinations; Ezetimibe; Germany; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Myocardial Infarction; Practice Patterns, Physicians'; Treatment Outcome | 2005 |
Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Treatment Outcome | 2005 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors | 2006 |
Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
Topics: Azetidines; Drug Combinations; Drug Synergism; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2007 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin | 2007 |
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias | 2007 |
Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Intestinal Absorption; Intestinal Mucosa; Intestines; Membrane Proteins; Membrane Transport Proteins; Niemann-Pick Diseases | 2007 |
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia.
Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids, Omega-3; Garlic; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Phytotherapy; Plant Preparations | 2007 |
Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Simvastatin; Treatment Outcome | 2007 |
Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Simvastatin; Treatment Outcome | 2007 |
[Other antihyperlipidemic drugs with novel mechanism].
Topics: Animals; Arteriosclerosis; Azetidines; Benzylamines; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; Chenodeoxycholic Acid; Cholesterol; Coronary Disease; Diphosphonates; DNA-Binding Proteins; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lithocholic Acid; Organic Anion Transporters, Sodium-Dependent; Oxygenases; Squalene Monooxygenase; Sterol Regulatory Element Binding Protein 1; Symporters; Thiophenes; Transcription Factors | 2001 |
27 trial(s) available for ezetimibe and Hyperlipidemias
| Article | Year |
|---|---|
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Coronary Disease; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged | 2022 |
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial.
Topics: Adult; Alanine Transaminase; Ezetimibe; Female; Health Education; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Nutrition Therapy; Nutritional Sciences; Prospective Studies; Republic of Korea | 2021 |
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
Topics: Animals; Bile Acids and Salts; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Liver; Mice; Receptor, Insulin; Simvastatin; Steroid 12-alpha-Hydroxylase | 2022 |
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.
Topics: Absorption; Adult; Aged; Anticholesteremic Agents; Azetidines; Biological Transport; Cholesterol; Cross-Over Studies; Double-Blind Method; Ezetimibe; Feces; Female; Humans; Hyperlipidemias; Intestinal Absorption; Intestinal Mucosa; Male; Middle Aged; Prospective Studies; Sterols | 2013 |
Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects.
Topics: Antibodies; Azetidines; Cholesterol, LDL; Ezetimibe; Fluorobenzenes; HLA-D Antigens; Humans; Hyperlipidemias; Hypolipidemic Agents; Immune System; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Can group medical clinics improve lipid management in diabetes?
Topics: Adult; Aged; Ambulatory Care Facilities; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Treatment Outcome; Veterans | 2014 |
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Azetidines; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2014 |
Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.
Topics: Adult; Aged; Atherosclerosis; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Fats; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hyperlipidemias; Male; Middle Aged; Pilot Projects; Postprandial Period; Treatment Outcome | 2016 |
Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Placebo Effect; Reference Values; Simvastatin; Statistics, Nonparametric; Time Factors; Treatment Outcome; Vasodilation | 2016 |
Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Topics: Acute Coronary Syndrome; Aged; Cholesterol, LDL; Coronary Angiography; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Japan; Male; Middle Aged; Prospective Studies; Quinolines | 2017 |
Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult | 2017 |
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Simvastatin | 2008 |
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.
Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Aryldialkylphosphatase; Azetidines; Body Mass Index; Cholesterol, HDL; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipidemias; Lactones; Linear Models; Lipoproteins, HDL2; Lipoproteins, HDL3; Male; Middle Aged; Obesity; Orlistat; Phospholipases A2; Time Factors; Treatment Outcome | 2008 |
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Activation; Ezetimibe; Female; Humans; Hyperlipidemias; Leukocytes; Male; Middle Aged; Prospective Studies; rho-Associated Kinases; Simvastatin; Triglycerides; Vasculitis; Vasodilation | 2009 |
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Lipoproteins; Male; Placebos; Simvastatin; Treatment Outcome; Triglycerides | 2009 |
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Niacin; Severity of Illness Index; Simvastatin; Tennessee; Time Factors; Treatment Outcome; Vitamin B Complex | 2010 |
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2010 |
Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides; Young Adult | 2012 |
Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.
Topics: Adult; Azetidines; Biomarkers; Endothelium, Vascular; Ezetimibe; Fasting; Female; Humans; Hyperemia; Hyperlipidemias; Hypolipidemic Agents; Japan; Lipids; Male; Middle Aged; Postprandial Period; Prospective Studies; Time Factors; Treatment Outcome; Vasodilation | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Statin-induced immunomodulation alters peripheral invariant natural killer T-cell prevalence in hyperlipidemic patients.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunomodulation; Male; Middle Aged; Natural Killer T-Cells; Prevalence; Simvastatin; Triglycerides | 2012 |
Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-48; Azetidines; Blood Glucose; Cholesterol; Cross-Over Studies; Double-Blind Method; Ezetimibe; Glucose; Humans; Hyperglycemia; Hyperlipidemias; Intestinal Mucosa; Lipid Metabolism; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Placebos; Postprandial Period; Prospective Studies; Time Factors; Triglycerides | 2012 |
Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Azetidines; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Ezetimibe; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Reference Values | 2004 |
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2005 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lipase; Male; Membrane Proteins; Membrane Transport Proteins; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Receptors, LDL; Serine Endopeptidases; Simvastatin | 2008 |
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Particle Size; Triglycerides | 2008 |
72 other study(ies) available for ezetimibe and Hyperlipidemias
| Article | Year |
|---|---|
Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab.
Topics: Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Mutation; Pedigree; Phenotype; Proprotein Convertase 9; Receptors, LDL; Rosuvastatin Calcium | 2022 |
The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Retrospective Studies; Russia | 2022 |
Fast dissolving oral films: An approach to co-load and deliver the atorvastatin and ezetimibe for better therapeutic response.
Topics: Animals; Atorvastatin; Excipients; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Rats; Solvents | 2022 |
First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor.
Topics: Anticholesteremic Agents; Cholesterol; Ezetimibe; Filipin; Humans; Hypercholesterolemia; Hyperlipidemias; Membrane Transport Proteins; Molecular Docking Simulation; Sesquiterpenes | 2022 |
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Ezetimibe; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Mammals; Simvastatin; Zebrafish | 2022 |
Novel application potential of cinaciguat in the treatment of mixed hyperlipidemia through targeting PTL/NPC1L1 and alleviating intestinal microbiota dysbiosis and metabolic disorders.
Topics: Cholesterol; Dysbiosis; Ezetimibe; Gastrointestinal Microbiome; Humans; Hyperlipidemias; Lipase; Lipidoses; Membrane Transport Proteins; Triglycerides | 2023 |
[Hypercholesterolemia and cardiovascular risk].
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9; Risk Factors | 2023 |
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cholesterol, LDL; Cricetinae; Diet, High-Fat; Disease Models, Animal; Ezetimibe; Heterozygote; Humans; Hyperlipidemias; Male; PCSK9 Inhibitors; Receptors, LDL; Treatment Outcome; Triglycerides | 2019 |
Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combination; Ezetimibe; Female; Health Expenditures; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Claim Review; Male; Medicare; PCSK9 Inhibitors; Sex Factors; Sociodemographic Factors; United States | 2021 |
Ezetimibe-Loaded Nanostructured Lipid Carrier Based Formulation Ameliorates Hyperlipidaemia in an Experimental Model of High Fat Diet.
Topics: Animals; Biological Availability; Diet, High-Fat; Drug Carriers; Drug Delivery Systems; Drug Liberation; Ezetimibe; Hyperlipidemias; Lipids; Male; Nanoparticles; Nanostructures; Nanotechnology; Particle Size; Rats; Rats, Wistar; Solubility; Triglycerides; X-Ray Diffraction | 2021 |
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Simvastatin | 2021 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
PCSK9 inhibitors- A new age in lipid management?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; PCSK9 Inhibitors; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk; Serine Proteinase Inhibitors | 2017 |
Model design for screening effective Antihyperlipidemic drugs using zebrafish system.
Topics: Animals; Atorvastatin; Biomarkers; Cholesterol; Diet, High-Fat; Disease Models, Animal; Drug Discovery; Ezetimibe; Fenofibrate; High-Throughput Screening Assays; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Triglycerides; Zebrafish | 2017 |
A pilot study of the effect of ezetimibe for postprandial hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-48; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Lipoproteins; Male; Membrane Cofactor Protein; Pilot Projects; Postprandial Period; Retrospective Studies; Treatment Outcome; Triglycerides | 2018 |
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Linear Models; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Prospective Studies; Triglycerides | 2019 |
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP Citrate (pro-S)-Lyase; C-Reactive Protein; Clinical Trials as Topic; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver | 2019 |
Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice.
Topics: Animals; Atherosclerosis; Cholesterol; Diet, Western; Disease Models, Animal; Ezetimibe; Hyperlipidemias; Intestinal Mucosa; Liver; Male; Membrane Transport Proteins; Mice; Mutation; Receptors, LDL; Up-Regulation | 2019 |
Design, synthesis and biological evaluation of some 2-azetidinone derivatives as potential antihyperlipidemic agents.
Topics: Animals; Azetidines; Binding Sites; Biomarkers; Crystallography, X-Ray; Disease Models, Animal; Drug Design; Ezetimibe; Female; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Membrane Proteins; Membrane Transport Proteins; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Polyethylene Glycols; Protein Conformation; Rats; Rats, Wistar | 2013 |
Drugs for lipids.
Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin | 2014 |
The c.-133A > G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Ezetimibe; Female; Genotype; Humans; Hyperlipidemias; Lipids; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Polymorphism, Single Nucleotide; Spectrophotometry, Ultraviolet | 2014 |
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Topics: Aged; Azetidines; Eicosapentaenoic Acid; Esters; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; New York; Random Allocation; Retrospective Studies | 2014 |
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels.
Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezetimibe; Health Behavior; Health Promotion; Humans; Hyperlipidemias; Niacin | 2014 |
Physicochemical characterization and pharmacological evaluation of ezetimibe-PVP K30 solid dispersions in hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Calorimetry, Differential Scanning; Ezetimibe; Hyperlipidemias; Male; Microscopy, Electron, Scanning; Rats; Rats, Wistar; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2015 |
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Medicare; Niacin; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; United States | 2015 |
Evaluation of physicochemical properties and in vivo efficiency of atorvastatin calcium/ezetimibe solid dispersions.
Topics: Animals; Atorvastatin; Cholesterol; Diet, High-Fat; Drug Combinations; Ezetimibe; Fatty Liver; Hyperlipidemias; Liver; Male; Povidone; Rats, Wistar; Solubility | 2016 |
The effect of ezetimibe monotheraphy on mean platelet volume in patients with hyperlipidaemia: a retrospective study of 45 patients.
Topics: Anticholesteremic Agents; Ezetimibe; Humans; Hyperlipidemias; Mean Platelet Volume; Retrospective Studies; Turkey | 2016 |
[Lipids and cerebrovascular disease - New therapeutic options in lowering LDL-cholesterol].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Risk Management | 2016 |
Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.
Topics: Adult; Aged; Cardiovascular Diseases; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Medication Therapy Management; Middle Aged; Outcome and Process Assessment, Health Care; Retrospective Studies; Time Factors; United States | 2017 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Should we treat all primary prevention patients with statins?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Primary Prevention; Triglycerides; Vitamin B Complex | 2009 |
Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Lipids; Liver Function Tests; Male; Middle Aged; Reoperation; Triglycerides | 2008 |
Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Female; Humans; Hyperlipidemias; Japan; Lipoproteins; Male; Postprandial Period; Risk Factors; Triglycerides | 2009 |
Letter by Tershakovec et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Risk Factors; Simvastatin; Vasculitis | 2009 |
Letter by Westerink and Visseren regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Simvastatin; Vasculitis | 2009 |
Letter by Settergren et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Simvastatin; Vasculitis | 2009 |
Lipid disorders.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Vitamin B Complex | 2009 |
Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
Topics: Allylamine; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pulse Therapy, Drug; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2009 |
Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Azetidines; Blood Glucose; Ezetimibe; Female; Fibrinolysis; Humans; Hyperlipidemias; Isoprostanes; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Plasminogen Activator Inhibitor 1; Protein Carbonylation; Tissue Plasminogen Activator | 2010 |
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Middle Aged; Niacin | 2010 |
Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome | 2011 |
Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease.
Topics: Aged; Asia; Azetidines; Cholesterol; Cohort Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
PTU induction provide quick screening of hypo and hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Antithyroid Agents; Azetidines; Cholesterol; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Propylthiouracil; Rats; Simvastatin | 2011 |
Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Treatment Outcome | 2013 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Mitochondrial Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Xanthomatosis | 2012 |
Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-48; Azetidines; Blood Glucose; Dietary Carbohydrates; Dietary Fats; Ezetimibe; Glucose; Humans; Hyperlipidemias; Insulin; Male; Middle Aged; Postprandial Period; Time Factors; Triglycerides; Young Adult | 2012 |
Use of combination therapy for dyslipidemia: a lipid clinic approach.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Triglycerides | 2002 |
Combination therapy for dyslipidemia: safety and regulatory considerations.
Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Safety | 2002 |
A novel therapeutic approach to dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Safety | 2003 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lovastatin; Muscular Diseases; Niacin | 2003 |
52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003.
Topics: Anticoagulants; Azetidines; Benzylamines; Cardiology; Cardiovascular Diseases; Chicago; Clinical Trials as Topic; Ezetimibe; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin | 2003 |
The antilipidemic effects of ezetimibe in patients with diabetes.
Topics: Anticholesteremic Agents; Azetidines; Diabetes Complications; Ezetimibe; Humans; Hyperlipidemias | 2003 |
Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hyperlipidemias; Medical Records; Regression Analysis; Retrospective Studies; Treatment Outcome | 2004 |
Two more drugs for dyslipidemia.
Topics: Azetidines; Drug Approval; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration | 2004 |
A statin for a patient with hyperlipidemia and hepatitis C?
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.
Topics: Adult; Anticholesteremic Agents; Azetidines; Case-Control Studies; Drug Resistance; Ezetimibe; Female; Humans; Hyperlipidemias; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Phenotype; Polymorphism, Genetic; Proteins | 2005 |
[How sure is the combined lipid lowering?].
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2005 |
Management of mixed hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2005 |
Ezetimibe-induced hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Middle Aged; Triglycerides | 2005 |
Supratherapeutic response to ezetimibe administered with cyclosporine.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cyclosporine; Drug Interactions; Ezetimibe; Heart Transplantation; Heptanoic Acids; Humans; Hyperlipidemias; Immunosuppressive Agents; Male; Middle Aged; Postoperative Complications; Pyrroles | 2005 |
Ezetimibe coadministered with fenofibrate: some safety questions.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Drug Combinations; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias | 2005 |
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Piperidines; Pyrazoles; Rimonabant | 2005 |
Ezetimibe: a turbocharger for the race to reach NCEP LDL goals.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Practice Guidelines as Topic; United States | 2005 |
A retrospective analysis of ezetimibe treatment in renal transplant recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Graft Rejection; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2006 |
[Ezetimibe with statins].
Topics: Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2006 |
The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Ambulatory Care Facilities; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Ezetimibe; Female; Humans; Hyperlipidemias; Male; Medical Records; Middle Aged; Patient Satisfaction; Retrospective Studies; Triglycerides | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy.
Topics: Alopecia Areata; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Hair; Humans; Hyperlipidemias; Male; Middle Aged; Simvastatin | 2007 |
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Ezetimibe; Hypercholesterolemia; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Liver; Mesocricetus; Obesity; Triglycerides | 2001 |